
Rinvoq is the first and only systemic medication approved in the EU for NSV

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

The phase 3 results show improvements in daily function, cognition and nighttime sleep

Cases of measles have been rising in Europe since 2023

Around 64 million people worldwide live with psoriasis

The initiative focuses on training AI models to aid in drug discovery and development

Marketing authorisation follows positive late-stage trial results

The drug is already approved in the EU across three other multiple myeloma indications

The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

Neurofibromatosis type 1 affects an estimated 135,000 people in the EU